Compare BioNTech SE - ADR (BNTX) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Schlumberger NV — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Schlumberger NV trades at $47.72 (market cap $71.08B). The key difference: Schlumberger NV is far larger — about 3.1× BioNTech SE - ADR's market cap, and Schlumberger NV pays a 2.48% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | SLB | |
|---|---|---|
Market Cap | $22.86B | $71.08B |
Sector | Health | Energy |
52-Week High | $119.34 | $58.01 |
52-Week Low | $83.89 | $31.72 |
Enterprise Value | $6.53B | $79.30B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
SLB trades at $47.36, down 0.84% on the day, with a neutral technical signal. The company reported revenue of $35.71 billion in 2025, with a net income margin of 9.26% and a P/E ratio of 20.86. Recent news includes a major EPC contract win for the Baleine Phase 3 development and a strategic alliance with Liberty Energy for data center infrastructure, highlighting diversification efforts.
The outlook is supported by strong analyst consensus with a $63.00 price target and 84.85% buy ratings, but risks include oil price volatility and a recent dip in profit margins. Earnings have consistently beaten expectations, providing fundamental strength amid market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
